短程高剂量脂质体两性霉素B治疗人类免疫缺陷病毒相关隐球菌性脑膜炎:一项2期随机对照试验
在坦桑尼亚和博茨瓦纳开展的2期非劣效随机试验,80例HIV相关隐球菌性脑膜炎成人随机接受三种短程高剂量脂质体两性霉素B方案或对照方案(3 mg/kg/日×14天),所有患者均联合口服氟康唑1200 mg/日×14天。各短程高剂量组的早期杀真菌活性均非劣效于对照组,10周死亡率29%且组间无统计学差异,单剂10 mg/kg方案耐受良好。
要点
- 单剂10 mg/kg脂质体两性霉素B的早期杀真菌活性非劣效于14天3 mg/kg/日方案。
- 各短程高剂量组与对照组10周死亡率无统计学差异,总死亡率29%。
- 所有方案耐受良好,单剂10 mg/kg方案将进入3期临床终点试验。
核心结论
- 单剂10 mg/kg脂质体两性霉素B耐受良好,在HIV相关隐球菌性脑膜炎中其早期杀真菌活性非劣效于14天3 mg/kg/日脂质体两性霉素B。
- 基于单剂10 mg/kg脂质体两性霉素B的诱导治疗正在被推进至一项3期临床终点试验。
研究设计与样本
- 在坦桑尼亚和博茨瓦纳开展的2期非劣效随机对照试验,纳入80例HIV感染的隐球菌性脑膜炎成人。
- 患者随机分为4组:单剂10 mg/kg第1天(单剂组,n=16);10 mg/kg第1天及5 mg/kg第3天(2剂组,n=18);10 mg/kg第1天及5 mg/kg第3天和第7天(3剂组,n=18);3 mg/kg/日×14天(对照组,n=17)。
- 所有患者同时口服氟康唑1200 mg/日×14天。
- 主要终点为脑脊液隐球菌感染的mean rate of clearance(早期杀真菌活性,EFA);非劣效界值为干预组与对照组EFA差值双侧95%CI上限<0.2 log10 CFU/mL/日。
主要发现
- 每日脂质体两性霉素B组的EFA为-0.41 log10 CFU/mL/日(标准差0.11;n=17)。
- 与对照组相比,单剂组EFA差值-0.11(95%CI,-.29至.07)log10 CFU/mL/日更快(n=16);2剂组-0.05(95%CI,-.20至.10)log10 CFU/mL/日更快(n=18);3剂组-0.13(95%CI,-.35至.09)log10 CFU/mL/日更快(n=18)。
- 所有短程高剂量组的EFA均非劣效于对照组。
- 10周死亡率为29%(n=23),组间无统计学差异。
- 所有组均耐受良好。
关键数值与推荐
- 非劣效界值定义为干预组与对照组EFA差值双侧95%CI上限<0.2 log10 CFU/mL/日。
- 单剂组与对照组EFA差值-0.11(95%CI,-.29至.07)log10 CFU/mL/日,95%CI上限.07<0.2,达到非劣效。
- 2剂组与对照组EFA差值-0.05(95%CI,-.20至.10)log10 CFU/mL/日,95%CI上限.10<0.2,达到非劣效。
- 3剂组与对照组EFA差值-0.13(95%CI,-.35至.09)log10 CFU/mL/日,95%CI上限.09<0.2,达到非劣效。
临床怎么用
- 单剂10 mg/kg脂质体两性霉素B联合口服氟康唑1200 mg/日×14天作为诱导治疗正在被推进至3期临床终点试验。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We performed a phase 2 noninferiority trial examining the early fungicidal activity (EFA) of 3 short-course, high-dose liposomal amphotericin B (L-AmB) regimens for cryptococcal meningitis (CM) in Tanzania and Botswana. METHODS: Human immunodeficiency virus (HIV)-infected adults with CM were randomized to (i) L-AmB 10 mg/kg on day 1 (single dose); (ii) L-AmB 10 mg/kg on day 1 and 5 mg/kg on day 3 (2 doses); (iii) L-AmB 10 mg/kg on day 1 and 5 mg/kg on days 3 and 7 (3 doses); or (iv) L-AmB 3 mg/kg/day for 14 days (control). All patients also received oral fluconazole 1200 mg/day for 14 days. Primary endpoint was mean rate of clearance of cerebrospinal fluid cryptococcal infection (EFA). Noninferiority was defined as an upper limit of the 2-sided 95% confidence interval (CI) of difference in EFA between intervention and control <0.2 log10 colony-forming units (CFU)/mL/day. RESULTS: Eighty participants were enrolled. EFA for daily L-AmB was -0.41 log10 CFU/mL/day (standard deviation, 0.11; n = 17). Difference in mean EFA from control was -0.11 (95% CI, -.29 to .07) log10 CFU/mL/day faster with single dose (n = 16); -0.05 (95% CI, -.20 to .10) log10 CFU/mL/day faster with 2 doses (n = 18); and -0.13 (95% CI, -.35 to .09) log10 CFU/mL/day faster with 3 doses (n = 18). EFA in all short-course arms was noninferior to control. Ten-week mortality was 29% (n = 23) with no statistical difference between arms. All arms were well tolerated. CONCLUSIONS: Single-dose 10 mg/kg L-AmB was well tolerated and led to noninferior EFA compared to 14 days of 3 mg/kg/day L-AmB in HIV-associated CM. Induction based on a single 10 mg/kg L-AmB dose is being taken forward to a phase 3 clinical endpoint trial. CLINICAL TRIALS REGISTRATION: ISRCTN 10248064.
引用
- Jarvis JN, Leeme TB, Molefi M, et al. Short-course High-dose Liposomal Amphotericin B for Human Immunodeficiency Virus-associated Cryptococcal Meningitis: A Phase 2 Randomized Controlled Trial. Clin Infect Dis. 2019. PMID: 29945252. doi:10.1093/cid/ciy515
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。